Section Arrow
APRE.NASDAQ
- Aprea Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2026/05/06 16:45 EDT
After Hours
Last
 0.8335
0 (0.00%)
Bid
0.82
Ask
0.8595
High 0.8335 
Low 0.8335 
Volume
Regular Hours (Closed)
Last
 0.8335
-0.0097 (-1.15%)
Day High 
0.912 
Prev. Close
0.8432 
1-M High
1.12 
Volume 
176.96K 
Bid
0.82
Ask
0.8595
Day Low
0.8014 
Open
0.912 
1-M Low
0.651 
Market Cap 
10.10M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.86 
20-SMA 0.87 
50-SMA 0.82 
52-W High 2.22 
52-W Low 0.548 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.93/-0.55
Enterprise Value
10.10M
Balance Sheet
Book Value Per Share
1.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ERNAErnexa Therapeutics Inc.6.04+2.05+51.38%0PE
After Hours 6.25 +0.21 +3.48%
MNKDMannKind Corp3.56+0.7+24.48%143PE
After Hours 3.2969 -0.2631 -7.39%
AVTXAvalo Therapeutics21.81+5.55+34.13%-- 
After Hours 21.6 -0.21 -0.96%
GERNGeron Corp1.58-0.07-4.24%-- 
After Hours 1.58 0 0.00%
IBRXImmunityBio8.38+0.8+10.55%-- 
After Hours 8.4 +0.02 +0.24%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications incancer treatment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.